Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - palonosetron hydrochloride - solution for injection in pre-filled syringe - 250 microgram(s) - serotonin (5ht3) antagonists; palonosetron

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - palonosetron hydrochloride, quantity: 280 microgram (equivalent: palonosetron, qty 250 microgram) - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium citrate dihydrate; sodium hydroxide; mannitol; disodium edetate; citric acid monohydrate - palonosetron baxter is indicated for:,? prevention of nausea and vomiting induced by cytotoxic chemotherapy,? prevention of postoperative nausea and vomiting (ponv) for up to 24 hours following surgery.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - palonosetron hydrochloride 0,056 mg/ml - eq. palonosetron 0,05 mg/ml - solution for injection - 250 µg - palonosetron hydrochloride 0.056 mg/ml - palonosetron

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - palonosetron hydrochloride 0,056 mg/ml - eq. palonosetron 0,05 mg/ml - solution for injection in pre-filled syringe - 250 µg - palonosetron hydrochloride 0.056 mg/ml - palonosetron

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - palonosetron hydrochloride 0,056 mg/ml - eq. palonosetron 0,05 mg/ml - solution for injection - 250 µg - palonosetron hydrochloride 0.281 mg - palonosetron

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

juta pharma gmbh - palonosetron hydrochloride 0,056 mg/ml - eq. palonosetron 0,05 mg/ml - solution for injection - 250 µg - palonosetron hydrochloride 0.056 mg/ml - palonosetron

United States - English - NLM (National Library of Medicine)

mgi pharma - palonosetron hydrochloride (unii: 23310d4i19) (palonosetron - unii:5d06587d6r) - injection - 0.25 mg in 5 ml - aloxi is indicated for: • moderately emetogenic cancer chemotherapy -- prevention of acute and delayed nausea and vomiting associated with initial and repeat courses • highly emetogenic cancer chemotherapy -- prevention of acute nausea and vomiting associated with initial and repeat courses aloxi is indicated for: • prevention of postoperative nausea and vomiting (ponv) for up to 24 hours following surgery. efficacy beyond 24 hours has not been demonstrated. as with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and vomiting must be avoided during the postoperative period, aloxi is recommended even where the incidence of postoperative nausea and/or vomiting is low. aloxi is contraindicated in patients known to have hypersensitivity to the drug or any of its components. [see adverse reactions (6.2 )] teratogenic effects: category b teratology studies have been perfo

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - palonosetron hydrochloride, quantity: 280.8 microgram (equivalent: palonosetron, qty 250 microgram) - injection, solution - excipient ingredients: citric acid monohydrate; mannitol; disodium edetate; sodium citrate dihydrate; hydrochloric acid; water for injections; sodium hydroxide - indicated for prevention of nausea and vomiting induced by cytotoxic chemotherapy.

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - palonosetron - vomiting; nausea; cancer - antiemetics and antinauseants, - palonosetron accord is indicated in adults for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy,the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.palonosetron accord is indicated in paediatric patients 1 month of age and older for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

juniper biologics pty ltd - netupitant, quantity: 300 mg; palonosetron hydrochloride, quantity: 0.56 mg (equivalent: palonosetron, qty 0.5 mg) - capsule - excipient ingredients: microcrystalline cellulose; sucrose laurate; povidone; croscarmellose sodium; purified water; silicon dioxide; sodium stearylfumarate; magnesium stearate; glyceryl caprylate/caprate; glycerol; polyglyceryl-3 dioleate; butylated hydroxyanisole; nitrogen; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; ethanol absolute; iron oxide black; sorbitol; 1,4-sorbitan; mannitol - akynzeo is indicated in adult patients for: prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.